On September 19, 2020, Hua Medtech and GE Healthcare announced a strategic cooperation to connect the RapidAI stroke intelligent image analysis platform, which is managed by Hua Medtech in China, to the Edison digital medical intelligent platform, so as to strengthen the fast quantitative analysis ability of multimodal images of stroke on the basis of accurate images. The overall stroke solution after the combination of the advantages of both parties can assist doctors in efficient patient screening, expand the range of benefited patients, improve the treatment quality for “patients beyond the time window” and improve the prognosis. At the same time, RapidAI, as a globally recognized quantitative assessment data for standardized stroke imaging, will also promote information sharing, facilitate regional referrals of stroke centers and multidisciplinary team consultations, and improve the efficiency of stroke prevention networks and stroke centers.
In recent years, it has become a breakthrough point for stroke diagnosis and treatment to accurately screen patients by multimodal imaging technology and formulate individualized treatment protocol. In 2018, the DAWN and DEFUSE 3 international clinical trials supported by RapidAI have confirmed that the time window of intravascular treatment can be widened from 6 hours to 24 hours by multimodal imaging technology. International and domestic guidelines for the diagnosis and treatment of acute ischemic stroke have also been updated: for patients with acute ischemic stroke within 6-24 hours after onset, if there is a large vessel occlusion of the anterior circulation and it meets the DAWN or DEFUSE 3 study enrollment criteria, mechanical thrombectomy is recommended, which opens a new chapter in the treatment of patients with stroke beyond the time window.
However, multimodal imaging and evaluation methods are complex and diverse, which require a lot of time for doctors to evaluate, and the accuracy of evaluation also varies significantly among different evaluators. Therefore, the combination of AI and neuroimaging technology came into being. The automatic evaluation function based on machine learning can greatly save the initial screening time and the doctor’s workload, and lay the foundation for the improvement of the evaluation accuracy and the treatment effect. At present, RapidAI is the gold standard for image analysis and screening of patients in global multicenter clinical trials. It has been involved in more than 14 multicenter clinical trials, including DAWN, DEFUSE 3, EXTEND, etc. It is regarded as a standardized tool for image quantitative analysis in the field of stroke clinical scientific research.
Precise intelligent imaging technology is the core of GE Healthcare’s stroke solutions. The connection between GE Healthcare’s Edison platform and RapidAI mainly aims to improve the intelligent imaging assessment capabilities of acute stroke diagnosis and treatment, which can achieve complete quantitative analysis of multimodal images within 30 seconds to 2 minutes per patient, and automatically send them to the PACS system, so as to help doctors grasp the patient’s perfusion situation in the first time and achieve rapid evaluation. In the future, RapidAI will serve as another innovative analysis tool for cerebrovascular diseases on GE Healthcare’s Edison platform, providing customers with more scientific research solutions.
Hua Medtech has been committed to providing complete solutions for stroke patients for a long time. In 2019, Hua Medtech reached a strategic cooperation with RapidAI company, and actively introduced the world’s advanced stroke intelligent image analysis software Rapid. The combination of RapidAI and PenumbraSystem, a device for treatment of ischemic stroke, and the establishment of the acute ischemic stroke solution model “intelligent diagnosis - efficient treatment”, truly provides an effective solution for Chinese stroke medicine and brings more hope Chinese stroke patients.
Hua Medtech Medical Devices (Shanghai) Co., Ltd. is a localization and innovative company dedicated to providing complete solutions for stroke. Since its establishment in 2017, the company has steadily rooted in the field of stroke and has continued to deepen its cultivation. With a global perspective, Hua Medtech cares about the world’s top technologies and products. It truly realizes localization and industrialization through “technology introduction - integration and innovation”, constantly narrows the gap between China and the world’s leading level, and truly benefits medicine and patients. At present, the company has established three complete platforms: marketing, production research and development, and data services.
As the exclusive agent of RapidAI in China, Hua Medtech has continuously promoted the development of RAPID software in China. RAPID (Rapid Processing of Perfusion and Diffusion) was developed by Stanford University Medical Center and has been approved by the FDA for screening patients of mechanical thrombectomy. It has been used in more than 1500 hospitals in over 50 countries around the world, with more than 650,000 scans per year.
For more information, please follow Hua Medtech’s WeChat official account (“Hua Medtech”), or visit the official website www.huamedtech.com.
GE Healthcare is the healthcare business unit of GE (NYSE: GE), with annual revenue of more than $17 billion. As a leading provider of medical imaging, monitoring, and digital medical technology, GE Healthcare achieves an all-round precision medicine from disease diagnosis, treatment to monitoring by providing intelligent devices, data analysis, software applications and services. GE Healthcare has a long history of more than 100 years and has more than 50,000 employees worldwide. The company is committed to helping patients, medical service providers and researchers around the world to improve healthcare outcomes more effectively. For the latest information of GE Healthcare, please follow WeChat and Weibo account of GE Healthcare, or visit the official website http://www3.gehealthcare.cn/.